ARA-290 vs TB-500
Both ARA-290 and TB-500 are used for anti-inflammatory. Here's how their evidence, dosing, and regulatory status actually compare.
ARA-290
Evidence BARA-290 (Cibinetide)
An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.
View full ARA-290 profile →TB-500
Evidence BThymosin Beta-4 Fragment
A synthetic fragment of thymosin beta-4 that promotes cell migration, blood vessel formation, and tissue repair. Often stacked with BPC-157 as the 'Wolverine Stack.'
View full TB-500 profile →Side-by-Side
| Attribute | ARA-290 | TB-500 |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy | Not FDA-approved — Category 2 (reclassification to Cat 1 expected 2026) |
| Typical Dose | Trial range: 1–4 mg subcutaneous daily | 2 mg twice weekly (subcutaneous) |
| Clinics Indexed | 9 | 183 |
| Categories | anti-inflammatory, neuroprotection | recovery, anti-inflammatory |
Key reported benefits — ARA-290
- ✓Small-fiber neuropathy improvement
- ✓Anti-inflammatory
- ✓No erythrocytosis
Key reported benefits — TB-500
- ✓Wound healing
- ✓Anti-inflammation
- ✓Tissue regeneration
- ✓Flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.